Optimum Management of Nausea and Vomiting in Cancer Chemotherapy

Drugs ◽  
1987 ◽  
Vol 34 (1) ◽  
pp. 136-149 ◽  
Author(s):  
Pierre L. Triozzi ◽  
John Laszlo
Keyword(s):  
Cancer Chemotherapy ◽  
Nausea And Vomiting ◽  
Optimum Management

Tropisetron plus haloperidol to ameliorate nausea and vomiting associated with high-dose alkylating agent cancer chemotherapy

1991 ◽  
Vol 27 (5) ◽  
pp. 561-565 ◽  
Author(s):  
Marco Bregni ◽  
Salvatore Siena ◽  
Massimo Di Nicola ◽  
Gianni Bonadonna ◽  
Alessandro M. Gianni
Keyword(s):  
Cancer Chemotherapy ◽  
Alkylating Agent ◽  
Nausea And Vomiting ◽  
High Dose

Antiemetics for Cancer Chemotherapy-Induced Nausea and Vomiting

Drugs in R&D ◽  
1999 ◽  
Vol 2 (4) ◽  
pp. 237-239
Author(s):  
Katharine J. Palmer ◽  
Raewyn Poole
Keyword(s):  
Cancer Chemotherapy ◽  
Nausea And Vomiting

Increased Nausea and Vomiting Induced by Naloxone in Patients Receiving Cancer Chemotherapy

1988 ◽  
Vol 10 (3) ◽  
pp. 206-208 ◽  
Author(s):  
Nathan L. Kobrinsky ◽  
Patricia B. Pruden ◽  
Mary S. Cheang ◽  
Martin Levitt ◽  
Agnes J. Bishop ◽  
...  
Keyword(s):  
Cancer Chemotherapy ◽  
Nausea And Vomiting

Management of Chemotherapy-Induced Nausea and Vomiting

2002 ◽  
Vol 15 (1) ◽  
pp. 32-41 ◽  
Author(s):  
Robyn H. Rosen
Keyword(s):  
Adverse Effects ◽  
Cancer Treatment ◽  
Cancer Chemotherapy ◽  
Nausea And Vomiting ◽  
Chemotherapy Agent ◽  
Antiemetic Agents

Nausea and vomiting are among the most distressing adverse effects of cancer chemotherapy. They can lead to both physical and psychological complications if uncontrolled. The exact mechanism for chemotherapy-induced nausea and vomiting is not known; it is thought to occur through numerous neuronal pathways acting on different sites. Chemotherapy-induced nausea and vomiting are broken down into 3 phases: acute, delayed, and anticipatory. The incidence of each phase depends largely on the chemotherapy agent used and is primarily treated with different antiemetic agents. Pharmacists can assist in optimizing antiemetic use by selecting appropriate antiemetics based on the emetogenicity of the cancer treatment and helping to individualize therapy to each patient’s specific needs.

Sign in / Sign up

Export Citation Format

Share Document